Tomorrow's leaders
We invest in our employees by giving them leadership training that enhances their skills and prepares them for future roles within the organization.
Search
In-Reach Africa initiatives successfully completed
We are proud to report the successful completion of Kuza Afya and Tiba Yako, two of our In-Reach Africa initiatives.
FDA accepts new chronic kidney disease treatment application
FDA accepts new chronic kidney disease treatment application
Boehringer Ingelheim Innovation Prize
Find out more about how we’re providing valuable resources to life-science innovators to enable new and emerging science
Boehringer Ingelheim announces appointments Board of Managing Directors
Boehringer Ingelheim announces appointments Board of Managing Directors
CHMP_opinion_nintedanib_ILD_PF
Nintedanib received a CHMP positive opinion for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
Kobe
The Kobe Pharma Research Institute takes part in the global research and development activities for human pharmaceuticals.
Our Health and Safety initiative - BE SAFE
Health and safety are of great importance to Boehringer Ingelheim.
Swine
Swine
Partnership African animal trypanosomiasis
New partnership working on solutions to combat African animal trypanosomiasis
Europe needs a vibrant research eco-system
At this week's EFPIA Days in Brussels, stakeholders will discuss how to re-establish a research-friendly eco-system in Europe.
2021 ABCD Young Scientist Award feline health
Young veterinary researchers Julia Klaus and Dr Yasmin Parr receive award for their work into feline SARS-CoV-2 infections and feline leukaemia virus.
Reduction of Salmonella in swine after vaccination
Authorities acknowledge reduction of Salmonella after vaccination with Enterisol® Ileitis
EC_approval_nintedanib_ILD_PF
European Commission approves nintedanib for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
Survey with Ipsos to gain insights human-animal bond
Boehringer Ingelheim partnered with the Ipsos Research Institute to carry out a survey to explore the human-animal bond.
Technologies
We are expanding our global network of technology partners Learn more about partnering with us.
Award: Boehringer Ingelheim is Global Top Employer 2022
Global Top Employer 2022
Henke-Sass Wolf develop needle free device
Boehringer Ingelheim partners with Henke-Sass, Wolf to develop innovative needle free injection device for pigs
Official partner to Cat Care for Life
Boehringer Ingelheim announces its new partnership with the CatCareforLife program.
Ukraine Help: We fly, we bike, we accommodate
The solidarity for Ukraine from Boehringer Ingelheim employees is incredible. Equally impressive is their practical help.
Over 100 billion birds vaccinated with VAXXITEK
Boehringer Ingelheim celebrates that over 100 billion birds have been vaccinated with VAXXITEK® HVT + IBD in October 2018.
Launch of first veterinary vaccines produced in China
Swine vaccine Ingelvac PRRS MLV, produced by Boheringer Ingelheim veterinary vaccine manufacturing plant in Taizhou is now officially supplied to the China market.
First Translational Medicine Award awarded
The Award recognizes the research that has the highest translational potential
Blue internal teat sealant now in dairy mastitis portfolio
Boehringer Ingelheim adds blue internal teat sealant to its dairy mastitis portfolio
Boehringer Ingelheim announces 2018 BVDzero Case Awards
Boehringer Ingelheim announces 2018 BVDzero Case Awards Boehringer Ingelheim will provide a total prize of €15,000 for the top 10 clinical cases entered Applications can be submitted on www.bvdzero.com